Company intelligence / Profile preview

CombiGene AB

Ownership: Private
Employees: ~9
Development stage: Preclinical

Overview

CombiGene is developing novel gene therapies and peptide treatments for severe life-altering diseases. Its lead programs include a gene therapy for epilepsy and two candidates for chronic pain, both currently in preclinical development. The company collaborates with Zyneyro on chronic pain therapeutics.[2]

Therapeutic areas: Neurology
Modalities: Gene therapy (adeno-associated virus-based)Peptide therapeutics[2]
Industry: Biotech

Drug pipeline

1 asset

CG01

Preclinical

Partnerships

Zyneyro ApS (collaboration on development of treatments for chronic pain)[2]

Beyond the preview

Go deeper on CombiGene AB.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CombiGene AB.